ASCO 2022 Conference Coverage


 

ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vaccine + Immune Checkpoint Blockade as Maintenance for Newly Diagnosed mCRC

155 views
June 13, 2022
Comments 0
Login to view comments. Click here to Login